Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Rituximab is known to be associated with high hepatitis B virus (HBV) reactivation rate in patients with resolved HBV infection and hematologic malignancy. However, data regarding HBV reactivation (HBVr) in rheumatic patients receiving rituximab is limited. To assess the HBVr rate in hepatitis B surface antigen (HBsAg)-negative patients receiving rituximab for autoimmune diseases in a large real-world cohort. Methods: From March 2006 to December 2019, 900 patients with negative HBsAg receiving at least one cycle of rituximab for autoimmune diseases in a tertiary medical center in Taiwan were retrospectively reviewed. Clinical outcome and factors associated with HBVr were analyzed. Results: After a median follow-up period of 3.3 years, 21 patients developed HBVr, among whom 17 patients were positive for hepatitis B core antibody (anti-HBc) and four were negative. Thirteen patients had clinical hepatitis flare, while eight patients had HBsAg seroreversion without hepatitis. Old age, anti-HBc positivity, undetectable serum hepatitis B surface antibody level at rituximab initiation and a higher average rituximab dose were associated with a higher HBVr rate. There was no significant difference in the HBVr risk between rheumatoid arthritis and other autoimmune diseases. Among anti-HBc-negative patients, subjects without HBV vaccination at birth had an increased risk of HBVr (4/368, 1.1%) compared with those who received vaccination (0/126, 0%). Conclusions: In HBV endemic areas where occult HBV is prevalent, anti-HBc-negative patients, may still be at risk for HBVr after rituximab exposure. HBVr may still be considered in HBsAgnegative patients developing abnormal liver function after rituximab exposure, even in patients with negative anti-HBc.
Abstract
Background/Aims: Rituximab is known to be associated with high hepatitis B virus (HBV) reactivation rate in patients with resolved HBV infection and hematologic malignancy. However, data regarding HBV reactivation (HBVr) in rheumatic patients receiving rituximab is limited. To assess the HBVr rate in hepatitis B surface antigen (HBsAg)-negative patients receiving rituximab for autoimmune diseases in a large real-world cohort. Methods: From March 2006 to December 2019, 900 patients with negative HBsAg receiving at least one cycle of rituximab for autoimmune diseases in a tertiary medical center in Taiwan were retrospectively reviewed. Clinical outcome and factors associated with HBVr were analyzed. Results: After a median follow-up period of 3.3 years, 21 patients developed HBVr, among whom 17 patients were positive for hepatitis B core antibody (anti-HBc) and four were negative. Thirteen patients had clinical hepatitis flare, while eight patients had HBsAg seroreversion without hepatitis. Old age, anti-HBc positivity, undetectable serum hepatitis B surface antibody level at rituximab initiation and a higher average rituximab dose were associated with a higher HBVr rate. There was no significant difference in the HBVr risk between rheumatoid arthritis and other autoimmune diseases. Among anti-HBc-negative patients, subjects without HBV vaccination at birth had an increased risk of HBVr (4/368, 1.1%) compared with those who received vaccination (0/126, 0%). Conclusions: In HBV endemic areas where occult HBV is prevalent, anti-HBc-negative patients, may still be at risk for HBVr after rituximab exposure. HBVr may still be considered in HBsAgnegative patients developing abnormal liver function after rituximab exposure, even in patients with negative anti-HBc.
참고문헌 (30)
- Yuen MF, "Hepatitis B virus infection", Nat Rev Dis Primers, 4, pp.18035~ (2018)
- Perrillo RP, "American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy", Gastroenterology, 148, pp.221~244 (2015)
- Fanouriakis A, "2019 update of the EULAR recommendations for the management of systemic lupus erythematosus", Ann Rheum Dis, 78, pp.736~745 (2019)
- Ramos-Casals M, "EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies", Ann Rheum Dis, 79, pp.3~18 (2020)
- Fasano S, "Rituximab in the treatment of inflammatory myopathies: a review", Rheumatology(Oxford), 56, pp.26~36 (2017)
- Rodríguez-Pintó I, "Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome", Ther Adv Musculoskelet Dis, 7, pp.26~30 (2015)
- Tieu J, "Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines", Rheumatology(Oxford), 59, pp.e24~e32 (2020)
- Smolen JS, "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update", Ann Rheum Dis, 79, pp.685~699 (2020)
- Di Bisceglie AM, "Recent US Food and Drug Administration warnings on hepatitis B reactivation with immunesuppressing and anticancer drugs : just the tip of the iceberg?", Hepatology, 61, pp.703~711 (2015)
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
- Kuo MH, "Moderate risk of hepatitis B virus reactivation in HBsAg-", HBcAb+ carriers receiving rituximab for rheumatoid arthritis, 2020, pp.10, 2456~
- Chen YM, "Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients : a long-term, real-world observation", Int J Rheum Dis, 22, pp.1145~1151 (2019)
- Tien YC, "Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative", HBcAb-positive patients undergoing biologic therapy for rheumatic diseases : a prospective cohort study, 2018, pp.20, 246~
- Varisco V, "Low risk of hepatitis B virus reactivation in HBsAg-negative", anti-HBc-positive carriers receiving rituximab for rheumatoid arthritis : a retrospective multicenter Italian study, 2016, pp.43, 869~874
- van Vollenhoven RF, "Longterm safety of rituximab : final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11years", J Rheumatol, 42, pp.1761~1766 (2015)
- Barone M, "Safety of longterm biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection", Hepatology, 62, pp.40~46 (2015)
- Ni YH, "Minimization of hepatitis B infection by a 25-year universal vaccination program", J Hepatol, 57, pp.730~735 (2012)
- Loomba R, "Hepatitis B reactivation associated with immune suppressive and biological modifier therapies : current concepts, management strategies, and future directions", Gastroenterology, 152, pp.1297~1309 (2017)
- Koutsianas C, "Reactivation of hepatitis B virus infection in rheumatic diseases : risk and management considerations", Ther Adv Musculoskelet Dis, 12 (2020)
- Fukuda W, "Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease : a multicentre, prospective, observational study in Japan", Ann Rheum Dis, 76, pp.1051~1056 (2017)
- Raimondo G, "Update of the statements on biology and clinical impact of occult hepatitis B virus infection", J Hepatol, 71, pp.397~408 (2019)
- Hsu HY, "Universal infant immunization and occult hepatitis B virus infection in children and adolescents : a population-based study", Hepatology, 61, pp.1183~1191 (2015)
- Ghaziasadi A, "High prevalence of occult hepatitis B infection(OBI)among healthy children and their parents in Alborz province, Iran; vertical OBI, myth or truth?", Liver Int, 40, pp.92~100 (2020)
- Hsu HY, "Chronologic changes in serum hepatitis B virus DNA, genotypes, surface antigen mutants and reverse transcriptase mutants during 25-year nationwide immunization in Taiwan", J Viral Hepat, 24, pp.645~653 (2017)
- Torbenson M, "Occult hepatitis B", Lancet Infect Dis, 2, pp.479~486 (2002)
- Hsu CY, "Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases : a nationally representative cohort study", Arthritis Res Ther, 21, pp.211~ (2019)
- Chen HC, "Increased risk of sudden sensorineural hearing loss in patients with hepatitis virus infection", PLoS One, 12, pp.e0175266~ (2017)
- Md Yusof MY, "Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases", Arthritis Rheumatol, 71, pp.1812~1823 (2019)
- Chen MH, "Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment", J Infect Dis, 215, pp.566~573 (2017)
- Wong GL, "Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure", J Hepatol, 72, pp.57~66 (2020)